Neurokinin B
Need Assistance?
  • US & Canada:
    +
  • UK: +

Neurokinin B

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Neurokinin B, one of the tachykinin family of peptides, binds a family of GPCRs-including neurokinin receptor 1 (NK1R), NK2R, and NK3R to mediate their biological effect but shows preference for the NK-3 receptor.

Category
Peptide Inhibitors
Catalog number
BAT-010553
CAS number
86933-75-7
Molecular Formula
C55H79N13O14S2
Molecular Weight
1210.42
Neurokinin B
IUPAC Name
(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
Synonyms
NKB; H-Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2; L-alpha-aspartyl-L-methionyl-L-histidyl-L-alpha-aspartyl-L-phenylalanyl-L-phenylalanyl-L-valyl-glycyl-L-leucyl-L-methioninamide; Neurokinin K; Neurokinin beta; β-Neurokinin; Neuromedin K; (5S,8S,14S,17S,20S,23S,26S,29S,32S)-26-((1H-imidazol-4-yl)methyl)-32-amino-17,20-dibenzyl-5-carbamoyl-23-(carboxymethyl)-8-isobutyl-14-isopropyl-29-(2-(methylthio)ethyl)-7,10,13,16,19,22,25,28,31-nonaoxo-2-thia-6,9,12,15,18,21,24,27,30-nonaazatetratriacontan-34-oic acid
Related CAS
101536-55-4 (trifluoroacetate)
Appearance
Lyophilized Powder
Purity
≥95%
Density
1.313±0.06 g/cm3
Boiling Point
1646.0±65.0 °C at 760 Torr
Sequence
DMHDFFVGLM-NH2
Storage
Store at -20°C
Solubility
Soluble in Water, DMSO
InChI
1S/C55H79N13O14S2/c1-30(2)21-38(50(77)62-36(47(57)74)17-19-83-5)61-43(69)28-59-55(82)46(31(3)4)68-54(81)40(23-33-15-11-8-12-16-33)65-51(78)39(22-32-13-9-7-10-14-32)64-53(80)42(26-45(72)73)67-52(79)41(24-34-27-58-29-60-34)66-49(76)37(18-20-84-6)63-48(75)35(56)25-44(70)71/h7-16,27,29-31,35-42,46H,17-26,28,56H2,1-6H3,(H2,57,74)(H,58,60)(H,59,82)(H,61,69)(H,62,77)(H,63,75)(H,64,80)(H,65,78)(H,66,76)(H,67,79)(H,68,81)(H,70,71)(H,72,73)/t35-,36-,37-,38-,39-,40-,41-,42-,46-/m0/s1
InChI Key
NHXYSAFTNPANFK-HDMCBQFHSA-N
Canonical SMILES
CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(=O)O)NC(=O)C(CC3=CN=CN3)NC(=O)C(CCSC)NC(=O)C(CC(=O)O)N
1. Neurokinin B and Neurokinin-3 Receptor Signaling: Promising Developments in the Management of Menopausal Hot Flushes
Waljit S Dhillo, Manish Modi Semin Reprod Med . 2019 May;37(3):125-130. doi: 10.1055/s-0039-3400241.
Vasomotor symptoms, including hot flushes and night sweats, pose a significant symptomatic burden to women undergoing menopause, and negatively impact on both their physical and psychological well-being. Management of these symptoms can be challenging, with the use of conventional hormone replacement therapy limited by duration of treatment and clinical contraindications. Recent advances in our understanding of the neuroendocrine regulation of the reproductive axis and thermoregulation postmenopause has helped identify a promising new therapeutic target to ameliorate hot flushes. Antagonism of the neurokinin B/neurokinin-3 receptor (NK3R) signaling pathway has emerged as an efficacious treatment in managing vasomotor symptoms, with evidence of rapid and sustained reduction in hot flush frequency and severity and improvements in secondary quality-of-life measures such as sleep. Within this review, we will explore the growing body of evidence supporting the use of NK3R antagonists in the management of vasomotor symptoms, and the possible utility in managing dysfunctional sex-hormone-dependent disorders and glycolipid metabolism disorders such as polycystic ovarian syndrome.
2. Neurokinin A and B
E Munekata Comp Biochem Physiol C Comp Pharmacol Toxicol . 1991;98(1):171-9.
The chemical features, pharmacological and biochemical characteristics of novel mammalian tachykinin peptides, neurokinin A and neurokinin B are described and are compared with those of substance P, a representative of tachykinin family.
3. Role of neurokinin B in ovine puberty
S M Hileman, M N Bedenbaugh, E C Bowdridge Domest Anim Endocrinol . 2020 Oct;73:106442. doi: 10.1016/j.domaniend.2020.106442.
Puberty is the process whereby an individual acquires the ability to reproduce, and the attainment of puberty in a timely manner is critical for both humans and livestock. For livestock, the initiation of puberty at the appropriate time aids in increasing lifetime productivity, thus maximizing profitability for producers. For humans, particularly females, early or late puberty is associated with several adverse health outcomes, including polycystic ovary syndrome, obesity, metabolic syndrome, osteoporosis, and psychosocial distress. Therefore, characterizing the mechanisms responsible for puberty onset would have a significant impact on human and animal health. It has been postulated that a group of neurons in the arcuate nucleus of the hypothalamus may play a role in puberty onset. These neurons contain kisspeptin, neurokinin B (NKB), and dynorphin and are often called KNDy neurons. Although the role of kisspeptin in puberty onset has been heavily researched, the involvement of NKB and dynorphin is not well defined. This mini-review focuses on the role of NKB in the initiation of puberty in female sheep. Stimulation of the receptor for NKB, NK3R, elicits LH secretion in a GnRH-dependent manner in prepubertal ewes, and both functional and neuroanatomical changes to the NKB system, particularly within the preoptic area, appear to occur as female sheep transition from a prepubertal to an adult state. Thus, NKB is likely an important component of puberty onset in sheep, although its integration with other systems that impact the pubertal process, such as photoperiod and nutrition, remains to be elucidated.
Online Inquiry
Verification code
Inquiry Basket